Herpes Simplex Virus 2 News and Research

RSS
Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
Genocea announces close of $35 million Series B venture financing round

Genocea announces close of $35 million Series B venture financing round

AiCuris announces completion of AIC316 Phase II genital herpes trial

AiCuris announces completion of AIC316 Phase II genital herpes trial

Anti-retroviral therapy yields 'Lazarus effect': Long-term household investment strategy replaces hopelessness

Anti-retroviral therapy yields 'Lazarus effect': Long-term household investment strategy replaces hopelessness

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Antigenics awarded $424,720 grant under QTDP program

Antigenics awarded $424,720 grant under QTDP program

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides' President delivers speech at ASNM Second Annual Conference

HSV1716 clinical trial for childhood cancer receives FDA grant

HSV1716 clinical trial for childhood cancer receives FDA grant

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Condoms can prevent transmission of herpes simplex virus 2: Study

Condoms can prevent transmission of herpes simplex virus 2: Study

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

Vical second-quarter revenues decrease to $2.1 million

Vical second-quarter revenues decrease to $2.1 million

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announces positive results of AG-707 genital herpes vaccine

Scientists discover mechanism of herpes virus cell entry machinery

Scientists discover mechanism of herpes virus cell entry machinery

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Fatness drives inactivity, not the other way around

Fatness drives inactivity, not the other way around

Map of herpes virus "cell-entry machinery" provides new target for antiviral drugs

Map of herpes virus "cell-entry machinery" provides new target for antiviral drugs

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses